Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo tested for Tough-to-Treat lung cancer

NCT ID NCT02143466

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and side effects of combining an approved lung cancer drug (osimertinib/AZD9291) with one of two other experimental drugs (AZD6094 or selumetinib). It involves about 344 adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has worsened despite prior targeted therapy. The main goal is to find safe dose combinations for future research.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Atlanta, Georgia, 30329, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Philadelphia, Pennsylvania, 19111, United States

  • Research Site

    Nashville, Tennessee, 37232, United States

  • Research Site

    Calgary, Alberta, T2N 4N2, Canada

  • Research Site

    Edmonton, Alberta, T6G 1Z2, Canada

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Habikino-shi, 583-8588, Japan

  • Research Site

    Hirakata-shi, 573-1191, Japan

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Nagoya, 460-0001, Japan

  • Research Site

    Nagoya, 464-8681, Japan

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Krakow, 31-202, Poland

  • Research Site

    Olsztyn, 10-357, Poland

  • Research Site

    Poznan, 60-569, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Chelyabinsk, 454087, Russia

  • Research Site

    Krasnoyarsk, 660133, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Saint Petersburg, 195271, Russia

  • Research Site

    Saint Petersburg, 197002, Russia

  • Research Site

    Saint Petersburg, 197022, Russia

  • Research Site

    Saint Petersburg, 197342, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Kaohsiung City, 82445, Taiwan

  • Research Site

    Kaohsiung City, 83301, Taiwan

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Kyiv, 03022, Ukraine

  • Research Site

    Vinnytsia, 21029, Ukraine

Conditions

Explore the condition pages connected to this study.

ADVANCED NON-SMALL CELL LUNG CANCER